Immunotherapy AdvancesImmunologyPeer-reviewed journal article
Lag3 and PD-1 pathways regulate NFAT-dependent TCR signalling programmes during early CD4+ T cell activation
Lozan SheriffiD, Alastair CoplandiD, David A.J. LeckyiD, Reygn DoneiD, L. S. George, Emma K. JenningsiD, Sophie RouvrayiD, Thomas A.E. ElliotiD, Elizabeth Jinks, Lalit PallaniD, David BendingiD
Abstract
Lag3 and PD-1 are immune checkpoints that regulate T cell responses and are current immunotherapy targets. Yet how they function to control early CD4+ T cell activation remains unclear. Here, we show that the PD-1 and Lag3 pathways exhibit layered control of the early CD4+ T cell activation process, with the effects of Lag3 more pronounced in the presence of PD-1 pathway co-blockade (CB). RNA-sequencing revealed that CB drove an early NFAT-dependent transcriptional profile, including promotion of ICOShi T follicular helper (Tfh) cell differentiation. NFAT pathway inhibition abolished CB-induced upregulation of NFAT-dependent co-receptors ICOS and OX40, whilst unaffecting the NFAT-independent gene Nr4a1. Mechanistically, Lag3 and PD-1 pathways functioned additively to regulate the duration of T cell receptor (TCR) signals during CD4+ T cell re-activation. Our data therefore reveal that PD-1 and Lag3 pathways converge to additively regulate TCR signal duration and NFAT-dependent transcriptional activity during early CD4+ T cell re-activation. HighlightsO_LIPD-1 and Lag3 pathways exhibit layered control of early CD4+ T cell activation C_LIO_LITheir co-blockade enhances NFAT-dependent TCR transcriptional programmes C_LIO_LIInhibition of NFAT signalling reverses the functional effects of PD-1 and Lag3 co-blockade C_LIO_LIMechanistically, PD-1 and Lag3 function to additively regulate TCR signal duration during re-activation of CD4+ T cells C_LI
- organism: mouse
- assay: bulk RNA-seq
- research focus: cell signaling & trafficking
- research focus: transcription & RNA processing
- research focus: cell type annotation
- approach: experimental assay
- Citations
- 5
- FWCI
- 0.77
- Field percentile
- top 31%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Antigen and Checkpoint Receptor Recalibration of T Cell Receptor Signal Strength
T. A. E. Elliot, E. K. Jennings, … D. Bending·bioRxiv·Mar 2, 2021
- FGL-1 binding to LAG-3 inhibits T cell activation via disruption of CD28 and TCR signaling
Samantha Nyovanie, Anika Hashem, … Michelle Krogsgaard·bioRxiv·Aug 5, 2025
- PD-1 and CTLA-4 exert additive control of effector regulatory T cells
J. A. Perry, Z. Lanzar, … C. A. Hunter·bioRxiv·Jul 22, 2022
- TCR-dependent and TCR-independent in-vitro T cell activation generate distinct functional, metabolic, and cytokine programs: Protein kinase C signalling augments anti-CD3+anti-CD28 responses
Nikita S. Ramteke, Dipankar Nandi·bioRxiv·Jul 20, 2026
- Differential Nr4a1 and Nr4a3 expression discriminates tonic from activated TCR signalling events in vivo
E. K. Jennings, T. A. E. Elliot, … D. Bending·bioRxiv·Jan 15, 2020
- Phosphatidylserine binding regulates TIM-3 effects on T cell receptor signaling
C. M. Smith, A. Li, … M. A. Lemmon·bioRxiv·May 7, 2021